title: Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans.
abstract: A single-dose, oral Salmonella typhi vaccine strain has been sought as a carrier or vector of cloned genes encoding protective antigens of other pathogens. Such a hybrid vaccine, administered orally, would stimulate immune responses both at the mucosal surface and in the systemic compartment and would potentially provide protection against multiple pathogens. S. typhi CVD 908 and CVD 906, which harbor deletions in aroC and aroD, were further engineered by deletion in htrA to produce strains CVD 908-htrA and CVD 906-htrA, which are unable to sustain growth and are severely impaired in their ability to survive in host tissues. These strains were fed to humans at doses of 5 x 10(7) to 5 x 10(9) CFU with buffer, and safety and immune responses were assessed. CVD 908-htrA and CVD 906-htrA were well tolerated in volunteers; mild diarrhea in 3 of 36 volunteers and mild fever in 1 volunteer were the only notable adverse responses. The vaccine strains were not detected in blood cultures and only transiently detected in stool. Serum immune responses to S. typhi lipopolysaccharide and H antigens were observed in 75 to 100% of volunteers who received 5 x 10(8) to 5 x 10(9) CFU, and cells secreting S. typhi-specific antibodies were found in all volunteers after ingestion of either strain. Sixty-three percent to 83% of volunteers developed lymphoproliferative responses to S. typhi flagellar and particulate antigens after the higher doses. These studies demonstrate the potential of CVD 908-htrA as a live vector for the delivery of heterologous genes, and a clinical trial of such a construct is planned.
authors.affiliation: Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA. ctacket@umppa1.ab.umd.edu
authors.forename: C O
authors.initials: CO
authors.lastname: Tacket
authors.forename: M B
authors.initials: MB
authors.lastname: Sztein
authors.forename: G A
authors.initials: GA
authors.lastname: Losonsky
authors.forename: S S
authors.initials: SS
authors.lastname: Wasserman
authors.forename: J P
authors.initials: JP
authors.lastname: Nataro
authors.forename: R
authors.initials: R
authors.lastname: Edelman
authors.forename: D
authors.initials: D
authors.lastname: Pickard
authors.forename: G
authors.initials: G
authors.lastname: Dougan
authors.forename: S N
authors.initials: SN
authors.lastname: Chatfield
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000235:genetics* / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D017353:Gene Deletion; D006360:Heat-Shock Proteins; D006801:Humans; D007111:Immunity, Cellular; D033903:Periplasmic Proteins; D012485:Salmonella typhi / Q000276:immunology*; D012697:Serine Endopeptidases / Q000235:genetics* / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D006360:Heat-Shock Proteins; D033903:Periplasmic Proteins; C061682:DegP protease; D012697:Serine Endopeptidases